Shares of Entrada Therapeutics rose after regulators removed a clinical hold and said its lead product candidate could be studied as a treatment for Duchenne muscular dystrophy. The stock was up 9.5% ...
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® ...
Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with ...
While main results from a platform study of four experimental drugs for amyotrophic lateral sclerosis are negative, it shows ...
Entrada Therapeutics (TRDA) announced that the United States Food and Drug Administration has lifted the clinical hold on ENTR-601-44 and ...
Capricor Therapeutics filed a BLA for deramiocel, showing promising results in slowing cardiac dysfunction in DMD ...
Salisbury Journal on MSN15h
New Forest woman sees royal interest in her book after raising thousands for charityAnn Blake, from Godshill, created her book, A Legacy of Love, which compiles poetry and artwork by several authors, including ...
It also bought an option on a liver disease therapy developed by Vivet Therapeutics and bought Bamboo Therapeutics to provide ...
Krishnan Guru-Murthy was left red-faced on Who Wants To Be A Millionaire after he was flummoxed by a question on his 'best' ...
In recent weeks, Children’s Hospital Los Angeles in East Hollywood has taken steps to improve care for some of its pediatric patients. In late January, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback